AU2002251821A1 - Nicotine immunogens and antibodies and uses thereof - Google Patents

Nicotine immunogens and antibodies and uses thereof

Info

Publication number
AU2002251821A1
AU2002251821A1 AU2002251821A AU2002251821A AU2002251821A1 AU 2002251821 A1 AU2002251821 A1 AU 2002251821A1 AU 2002251821 A AU2002251821 A AU 2002251821A AU 2002251821 A AU2002251821 A AU 2002251821A AU 2002251821 A1 AU2002251821 A1 AU 2002251821A1
Authority
AU
Australia
Prior art keywords
antibodies
immunogens
nicotine
nicotine immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251821A
Inventor
Kim D. Janda
Peter Wirsching
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2002251821A1 publication Critical patent/AU2002251821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
AU2002251821A 2001-01-26 2002-01-25 Nicotine immunogens and antibodies and uses thereof Abandoned AU2002251821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26457501P 2001-01-26 2001-01-26
US60/264,575 2001-01-26
PCT/US2002/002146 WO2002058635A2 (en) 2001-01-26 2002-01-25 Nicotine immunogens and antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2002251821A1 true AU2002251821A1 (en) 2002-08-06

Family

ID=23006669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251821A Abandoned AU2002251821A1 (en) 2001-01-26 2002-01-25 Nicotine immunogens and antibodies and uses thereof

Country Status (2)

Country Link
AU (1) AU2002251821A1 (en)
WO (1) WO2002058635A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312297A (en) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugated hapten vehicles and their use
EP2319867A1 (en) * 2007-11-29 2011-05-11 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
TWI578997B (en) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 Conjugates for the prevention or treatment of nicotine addiction
US10093947B2 (en) * 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
CN111432883B (en) * 2017-08-15 2024-10-01 安蒂多特疗法公司 Novel nicotine binding antibodies
CN112512549A (en) 2018-06-06 2021-03-16 安蒂多特疗法公司 Methods for improving circulation and treating cardiovascular disease
CN112174763B (en) * 2020-11-27 2021-04-27 北京邦克凯姆医药科技有限公司 Racemization method and application of pyridine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
SE9801923D0 (en) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
WO2002058635A2 (en) 2002-08-01
WO2002058635A3 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002251913A1 (en) Hybrid antibodies and uses thereof
EP1432444A4 (en) Anti-a-beta antibodies
HK1074206A1 (en) Anti-trail-r antibodies
AU2002360023A1 (en) Smoking implement
AUPR395801A0 (en) Antibodies against cancer
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002365649A1 (en) Anti-dota antibody
AU2003253621A1 (en) Modified "s" antibodies
AU2001285115A1 (en) Jewelry setting
PT1430082E (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2002349543A1 (en) Tumor antigens
AU2002251821A1 (en) Nicotine immunogens and antibodies and uses thereof
AU2001296709A1 (en) Gemstone
AU2002359694A1 (en) Compounds and methods
AU2001210572A1 (en) Ornament
AU2002221132A1 (en) Novel antibody
AU2001245781A1 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU2001295042A1 (en) Anti-stilbene antibodies
AU2002362494A1 (en) Tumor-peptide antigens from the human prdi-bf1-protein
AU2002100721A4 (en) Nicotine and smoking - bye
AU2002219568A1 (en) Cigarette
AU2001100149A4 (en) Burley line bags
AU2002257356A1 (en) Compounds and methods for preparing methanesulfonamides
AU2002352970A1 (en) Prongless gemstone setting

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase